Migraine prophylaxis step therapy context — prior preventive med or CGRP trial

For chronic migraine prophylaxis, the policy requires failure of two oral preventive medications (each tried for at least 8 weeks) OR prior treatment with a CGRP antagonist before Botox; document medication names, durations, and outcomes in the PA request.

• Record two failed oral preventive medication trials (≥8 weeks each) or prior CGRP antagonist treatment
• Include dates, dosages, and reason for failure in documentation

Prior authorization renewal requirements

Renewal of prior authorization requires that the member continues to meet the universal and indication-specific criteria, that the original authorization duration has not been exceeded, and that there is absence of unacceptable toxicity from the drug.

• Document continued fulfillment of universal and indication-specific criteria
• Ensure authorization duration has not been exceeded (see Section I)
• Confirm no unacceptable toxicity (see policy examples of toxin spread, severe neuromuscular effects, severe hypersensitivity, etc.)

Prior authorization for J0585 — include indication & dose

Prior authorization applies to onabotulinumtoxinA billed with HCPCS code J0585; when requesting PA providers must supply the indication, dose (billable units), and supporting documentation of medical necessity.

• HCPCS: J0585 — Injection, onabotulinumtoxinA, 1 unit
• Include indication and proposed dose (units) in the PA request
• Attach supporting clinical documentation per indication

Prior authorization may be required (NQTL rationale)

Utilization management via prior authorization may be applied to Botox based on the NQTL assessment of indication, safety/efficacy, and cost; providers should expect PA requirements where indicated in the policy.

• NQTL checklist lists Indication, Safety/Efficacy, and Cost as reasons to consider PA
• Consult policy sections for PA applicability per indication

Covered diagnoses — use Appendix 1 ICD-10 codes

The policy’s Appendix 1 enumerates the ICD-10 diagnosis codes considered covered; prior authorization and medical necessity determinations must be supported by one of these covered diagnoses.

• Use an Appendix 1 ICD-10 code that corresponds to the member’s diagnosis when submitting PA/claims
• Coverage is governed by the clinical sections and criteria in the policy

Hyperhidrosis step therapy — topical trial and iontophoresis

For primary axillary and palmar hyperhidrosis, providers must document a trial and failure of a topical agent for at least 1 month; for palmar hyperhidrosis the member must also have failed iontophoresis before Botox is considered.

• Topical agent trial ≥1 month (examples: 20% aluminum chloride, glycopyrronium, sofpironium)
• Palmar hyperhidrosis: documented failure of iontophoresis required

Document required prior therapy trials per indication

Certain indications require documented prior therapy trials before coverage (e.g., topical agents and iontophoresis for palmar hyperhidrosis; failure of supportive measures and ≥1 month trial of conventional pharmacologic therapy for chronic anal fissure; 3-month trial of conventional noninvasive therapy for TMD).

• Chronic anal fissure: rule out other causes, fail supportive measures, fail ≥1 month conventional pharmacologic therapy
• Temporomandibular disorders: fail 3-month trial of noninvasive therapy

Baseline assessment for chronic migraine (objective measures required)

Document baseline objective assessment for chronic migraine prophylaxis (e.g., HIT-6, monthly headache days, MIDAS, MPFID) and that other causes of headache have been ruled out prior to initial PA.

• Record baseline score(s) on objective tool (HIT-6, MIDAS, MHD, MPFID)
• Confirm diagnostic criteria for chronic migraine (≥15 headache days/month for >3 months with ≥8 migraine-feature days/month)

Required documentation for renewal — continued criteria, safety, and outcomes

For renewal requests, providers must document continued fulfillment of universal and indication-specific criteria, absence of unacceptable toxicity, and objective evidence of disease improvement using indication-appropriate measures.

• Renewal must show disease response per indication (e.g., HIT-6 or MHD for migraine; reduced sweat for hyperhidrosis; healing or symptom improvement for anal fissure)
• Document lack of unacceptable toxicity (see examples in policy renewal section)

Clinical outcomes documentation — use indication-specific measures

Clinical outcomes documentation submitted for PA/renewal should demonstrate the indication-specific response measures (for example, significant reduction in spontaneous palmar sweat and improvement in ADLs for palmar hyperhidrosis; decrease in headache frequency/intensity on objective tools for chronic migraine).

• Severe palmar hyperhidrosis: measurable reduction in spontaneous palmar sweat and improved activities of daily living
• Chronic migraine: significant decrease in number/frequency/intensity of headaches on HIT-6/MHD/MIDAS/MPFID

Required diagnostic coding documentation — use Appendix 1 codes

Providers must include diagnostic documentation that supports one of the covered ICD-10 diagnoses listed in Appendix 1 when requesting PA or submitting claims.

• Attach the appropriate Appendix 1 ICD-10 code that matches the clinical diagnosis
• Ensure supporting clinical notes concur with the billed diagnosis code

Medicare references — consult CMS/MAC guidance for Part B

When submitting Medicare Part B claims or treating Medicare members, consult the CMS coverage database and applicable NCDs/LCDs/LCAs and regional MAC guidance as these govern Part B coverage and may affect PA and claims submission.

• Search CMS coverage database for applicable NCD/LCD/LCA documents
• Follow regional MAC/LCD guidance where applicable

Contraindications and concurrent therapy — grounds for denial

Requests may be denied if the member has an FDA-labeled contraindication to the requested agent (e.g., hypersensitivity to botulinum toxin, active infection at the proposed injection site, or for intradetrusor use a current UTI or urinary retention) or is on concurrent treatment with another botulinum toxin.

• Hypersensitivity to any botulinum toxin product or components
• Active infection at proposed injection site
• For intradetrusor injections: untreated urinary tract infection or urinary retention
• Concurrent treatment with another botulinum toxin

Renewal denial risks — duration exceeded or unacceptable toxicity

Renewal requests may be denied if the duration of authorization has been exceeded or if the member experiences unacceptable toxicity attributable to the drug.

• Exceeded authorization duration per Section I may lead to denial
• Unacceptable toxicity examples in policy include toxin spread effects and severe neuromuscular or hypersensitivity reactions

Dose limits — adhere to adult and pediatric maxima

Doses that exceed the policy’s maximum cumulative limits may be denied — for adults the maximum cumulative dose is not to exceed 400 Units in a 12-week (3-month) interval; pediatric limits are the lower of 10 Units/kg or 340 Units per 12 weeks.

• Adult maximum cumulative dose: 400 Units per 12 weeks (unless otherwise stated, e.g., ventral hernia)
• Pediatric maximum cumulative dose: lower of 10 Units/kg or 340 Units per 12 weeks

Prior authorization considerations — NQTL rationale

PA is applied as a utilization management tool based on NQTL factors — indication, safety/efficacy, and cost — and providers should anticipate PA requirements where indicated in the policy.

• NQTL checklist explicitly cites Indication, Safety/Efficacy, and Cost as considerations for PA

Dual coding requirement — primary G/M codes need secondary G/I code

Claims billed with primary G and M codes require an appropriate secondary G or I code to be payable; failure to include the required secondary code may render the claim non-payable.

• Ensure any claim using primary G or M codes includes the required secondary G or I code as specified

Office administration: follow indication dosing and pediatric localization techniques

Administration and dosing must follow the indication-specific guidance; for pediatric injections, use localization techniques such as needle EMG, nerve stimulation, or ultrasound as recommended to accurately target muscles.

• Pediatric localization options: needle EMG, nerve stimulation, ultrasound
• Tailor dose to muscle size, number, location, and prior response